Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Travere Therapeutics's pe ratio was 15.8× on Oct 31, 2016, against 248.4× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2016 | Oct 31, 2016 | 15.8× | +0.7 |
| 2015 | Dec 31, 2015 | 15.2× | – |
See a number that looks wrong?